From trials to clinics: investigators' perspectives on translating psychedelic research into clinical care

Psychedelics such as 3,4-methylenedioxymethamphetamine (MDMA) and psilocybin are showing promising results in clinical trials for the treatment of mental health disorders, including post-traumatic stress disorder, addiction, and treatment-resistant depression. US Food and Drug Administration approval may be on the horizon. Yet, little is known about how these treatments will move from tightly controlled clinical trials to routine clinical care.

This study examines how psychedelic clinical investigators anticipate this transition and what challenges they expect.

We conducted semi-structured interviews with 21 clinical investigators based at major academic psychedelic research centers across the United States. We transcribed and analyzed these conversations using inductive and deductive coding to identify major themes.

Investigators generally viewed psychedelic medicine as distinct from existing treatments, particularly in terms of drug effects, treatment models, and broader goals. They highlighted three major translational challenges: (i) uncertainty surrounding the role of psychotherapy, (ii) the cost of treatment and its scalability, and (iii) the effects of both hype and stigma on clinical uptake.

Despite these challenges, most investigators anticipated that psychedelic medicine could eventually fit into routine clinical care and may even improve it.